NCT05345171Phase 3Active not recruiting

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

Study sponsor: Ultragenyx Pharmaceutical Inc · RARE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-09Estimated
Enrollment · participants37Actual
Source updated2026-09-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 32 participants (planned). After: 37 participants (actual).

Check registry source

· 2 fields changed

Completion date type changed

Before: Actual. After: Estimated.

Primary completion date changed

Before: 19 Feb 2025. After: Sep 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview